D3S-001, a KRAS G12C inhibitor with rapid target engagement kinetics, overcomes nucleotide cycling and demonstrates robust preclinical and clinical activities
Cancer Discov., May 08 2024, | https://doi.org/10.1158/2159-8290.CD-24-0006
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
Nat. Commun., 11 November 2023 | https://doi.org/10.1038/s41467-023-42900-4
BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
Clin. Cancer Res., 2023 May 30;CCR-22-3901 | https://doi.org/10.1158/1078-0432.CCR-22-3901
Preclinical study of a biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC
Clin. Cancer Res., NOVEMBER 17 2022 | https://doi.org/10.1158/1078-0432.CCR-22-2180
